FRAMEWORK-CRC

Fruquintinib Real-World Outcomes in mCRC – A Prospective
Study of One-Year Progression-Free Survival and Overall
Survival in Polish Patients.

Dear Sir or Madam,

we would like to invite you to participate in a multicenter, prospective observational study of metastatic colorectal cancer.

The registration and login panel for the eCRF system is available on the right.

Study Sponsor:

Takeda Pharma sp. z o.o.
ul. Prosta 28, 00-838 Warsaw, Poland

Clinical Research Organization:

(contracted by the Sponsor)

Biostat Sp. z o.o.
ul. Kowalczyka 17, 44-206 Rybnik, Poland

phone: +48 530 714 118
e-mail: [email protected]

VV-MEDMAT-137808, 06/2026

2026 Takeda Pharmaceutical Company Limited. All rights reserved.
Content is protected by copyright and may not be copied, modified, or distributed without prior written permission, except for limited non-commercial use with proper notice.